A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Completed

• Conditions: 10024967; IPF; lung fibrosis

• Registration Number: NL-OMON43714
• Lead Sponsor: Promedior, Inc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 21

Inclusion Criteria

1. Subject is aged 40-80 years.
2. Subject has IPF satisfying the ATS/ERS/JRS/ALAT diagnostic criteria (Raghu, Collard et al. 2011).
In the absence of a surgical lung biopsy, HRCT must be *consistent with UIP* defined as meeting either criteria A, B, and C, or criteria A and C, or criteria B and C below:
A. Definite honeycomb lung destruction with basal and peripheral predominance.
B. Presence of reticular abnormality AND traction bronchiectasis consistent with fibrosis, with basal and peripheral predominance.
C. Atypical features are absent, specifically nodules and consolidation. Ground glass opacity, if present, is less extensive than reticular opacity pattern.
3. If on pirfenidone or nintedanib, subject must have been on a stable dose of pirfenidone or nintedanib for at least 3 months prior to screening without increase in FVC% predicted on two consecutive PFTs, including screening PFTs. Subjects may not be on both pirfenidone and nintedanib.
4. If not currently receiving pirfenidone or nintedanib, subject must have been off pirfenidone or nintedanib for * 4 weeks before baseline.
5. Subject has a FVC * 50% and * 90% of predicted.
6. Subject has a DLCO * 25% and * 90% of predicted.
7. Minimum distance on 6MWT of 150 meters, with or without supplemental oxygen
8. Subject has a forced expiratory volume in 1 second (FEV1)/FVC ratio > 0.70.
9. Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if * 55 years or 12 months if > 55 years, must have a negative serum pregnancy test within four weeks prior to the first dose of study drug and must agree to use adequate methods of birth control throughout the study. Adequate methods of contraception include use of oral contraceptives or Depo-Provera, with an additional barrier method (diaphragm with spermicidal gel or condoms with spermicide), double-barrier methods (diaphragm with spermicidal gel and condoms with spermicide), partner vasectomy, and total abstinence (only if total abstinence is the preferred method and usual lifestyle of the subject).
10. Subject has a life expectancy of at least 9 months
11. Subject, according to the investigator*s best judgment, can comply with the requirements of the protocol.
12. Subject and the treating physician considered all medicinal treatment options and/or possibly a lung transplantation prior to considering participation in the study. If the subject is on a lung transplant list, the Investigator anticipates the subject will be able to complete the study prior to transplant.
13. Subject has provided written informed consent to participate in the study.

Exclusion Criteria

1. Subject has emphysema * 50% on HRCT or the extent of emphysema is greater than the extent of fibrosis according to the reported results of the most recent HRCT.
2. Subject has a history of cigarette smoking within the previous 3 months.
3. Subject has received investigational therapy for IPF within 4 weeks before baseline.
4. Subject is receiving systemic corticosteroids equivalent to prednisone > 10 mg/day or equivalent within 2 weeks of baseline.
5. Subjects received Immuno-suppressants (e.g. methotrexate, azathioprine, cyclophosphamide, cyclosporine, everolimus or other immunosuppressants including those used after organ transplant) are prohibited within 4 weeks of baseline and during the study.
6. Subject has a history of a malignancy within the previous 5 years, with the exception of basal cell skin neoplasms. In addition, a malignant diagnosis or condition first occurring prior to 5 years must be considered cured, inactive, and not under current treatment.
7. Subject has any concurrent condition other than IPF that, in the Investigator*s opinion, is unstable and/or would impact the likelihood of survival for the study duration or the subject*s ability to complete the study as designed, or may influence any of the safety or efficacy assessments included in the study.
8. Subject has baseline resting oxygen saturation of < 89% on room air or with supplemental oxygen.
9. Subjects that are unable to refrain from use of the following:
a. Short acting bronchodilators on the day of and within 12 hours of pulmonary function, DLco, and 6 minute walk assessments.
b. Long acting bronchodilators on the day of and within 24 hours of these assessments.
10. Subject has a known post bronchodilator (short acting beta agonist [SABA] * albuterol or salbutamol) increase in FEV1 of >10% and in FVC of >7.5%.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary endpoint is the mean change in FVC % predicted from Baseline to<br /><br>Week 28.</p><br>